The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2021Compounds that Enhance the Activity of GCase as a Treatment for Parkinson’s Disease
Study Rationale:
Beta-glucocerebrosidase (GCase), a protein that processes some of the key components of cell membranes, is required for normal brain function. Reduced activity of this protein... -
Therapeutic Pipeline Program, 2021Identifying Small Molecule Binders of the LRRK2 WD Domain
Study Rationale:
Individuals with genetic variations or mutations in a gene called LRRK2 are at increased risk of developing Parkinson’s disease (PD). Because these alterations enhance the activity of... -
Parkinson's Pathway Biomarkers, 2021Phospho-proteome Analysis of PBMCs in LRRK2 Mutation Carriers: Expansion & Validation of Findings of the Barcelona LRRK2 Biorepository
Study Rationale: We established a biorepository of blood cells from G2019S LRRK2-PD patients recruited at the Hospital Clínic de Barcelona (Barcelona). Using this cohort, we performed a phospho...
-
Therapeutic Pipeline Program, 2021Proof of Concept and Translational Validation of USP30 to Offset Dysfunction in the PRKN Pathway
Study Rationale:
USP30 is an enzyme which acts in the opposite way to Parkin (PRKN), a gene linked to young-onset Parkinson’s disease (PD). Mutations in the PRKN gene impact mitochondria (the cell’s... -
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Reprogramming the Brain’s Non-neuronal Support Cells to Generate Functional Dopamine-producing Neurons
Study Rationale:
We have recently demonstrated that a method for converting supportive, non-neuronal brain cells into functional dopamine-producing neurons leads to the complete reversal of symptoms... -
PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2021San Antonio Ligand Consortium (SALC)
Study Rationale:
The development of alpha-synuclein and 4-repeat tau (4RT) positron-emission tomography (PET) imaging agents would benefit people with Parkinson’s disease (PD), progressive...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.